Why cover GLP-1s? They’ll lower employer healthcare costs, study says

Summary

Aon analysed claims for more than 50 million people (including about 192,000 GLP-1 users) over a little more than two years. By 30 months, medical cost growth for people with diabetes using GLP-1s was 6% lower than for diabetics not using the drugs. Consistent use mattered: members with roughly 80% adherence saw medical cost growth 9% lower. Similar patterns showed up for people using GLP-1s for weight loss, and users generally had fewer hospitalisations for major adverse cardiovascular events.

The report also flagged notable cancer-related findings for women: roughly a 50% lower incidence of ovarian cancer and about a 14% lower incidence of breast cancer among GLP-1 users within the study period. Despite those outcomes, only around 23% of employers currently offer GLP-1 coverage, making the research relevant to benefits strategy discussions.

Key Points

Aon looked at >50 million people, including ~192,000 GLP-1 users, across ~30 months.
At 30 months, diabetics on GLP-1s had 6% lower medical cost growth vs diabetics not using GLP-1s.
High adherence (≈80%) correlated with a 9% reduction in medical cost growth.
GLP-1 users—whether for diabetes or weight management—had fewer hospitalisations for major adverse cardiovascular events.
Aon observed substantially lower incidence of ovarian cancer (~50%) and lower breast cancer (~14%) among women using GLP-1s during the analysis window.
Only 23% of employers currently cover GLP-1s; Aon recommends pairing coverage with adherence and wellbeing programmes to maximise value.
Aon projects U.S. employer healthcare costs will rise ~9.5% in 2026; prescription drugs (including GLP-1s) are a major driver of benefit spend—so employers need careful cost–benefit analysis.

Context and Relevance

This analysis matters for HR and benefits teams weighing short-term drug spend against longer-term medical-cost trends. GLP-1s are high-cost prescriptions that are already reshaping benefits budgets, but Aon’s data suggest sustained, supported use can reduce overall medical-cost growth and serious cardiovascular events—outcomes that directly affect absence, disability, and healthcare spend for organisations.

For employers deciding whether to add GLP-1 coverage, the study underscores two themes: the clinical and financial upside from sustained adherence, and the need to design coverage alongside support programmes (adherence, weight-management, cardiovascular risk management) rather than treating the drug as a standalone line item.

Why should I read this

Short and blunt: if you manage benefits or budget for staff healthcare, this is worth five minutes. The headline — pricey drugs that may cut long-term employer costs — is the kind of trade-off your finance and benefits teams are arguing about right now. The study gives data you can use in an internal cost–benefit conversation and flags that coverage alone isn’t enough; you need adherence and wellbeing programmes to get the payoff.